Bioscience Vaccines, Inc., a West Lafayette, IN-based developer of a biologic material that may aid in the efficacy of vaccines by stimulating an immune response, has raised $400,000 in seed financing.
The investment was made by BioCrossroads’ Indiana Seed Fund I, a State-backed life sciences seed stage investment fund.
Bioscience Vaccines, Inc. is developing and studying a novel technology for the development of vaccine supplements (adjuvants) that will hopefully increase the effectiveness of vaccines against illness caused by infectious diseases and epidemics.
The new capital will be used to accelerate the company’s product development and complete required studies to prepare the product for a Phase I human clinical trial.
The proceeds from the investment will also support the company in beginning studies for additional vaccine products for applications in cancer prevention.
Bioscience Vaccines’ adjuvant product is based upon Cook Biotech’s proprietary extracellular matrix (ECM) technology that has been exclusively licensed to the company. ECM is a complex material that helps the human body repair itself by attracting new cells and facilitating growth and tissue regeneration.
Bioscience Vaccines is currently in discussions to locate its headquarters at Innovation Park at Notre Dame in South Bend, IN.